Various retrospective clinical studies have shown that pre-and in-hospital use of low-dose aspirin was associated with a reduced mortality [1-4], but there is no evidence that NSAIDs may have a similar benefi t [1,5]. We studied the medical records of 979 patients with severe sepsis or septic shock who were admitted to a university hospital surgical intensive care unit (ICU). Exclusion criteria were ICU stay of less than 48 hours, age of more than 18 years, and pregnancy. Th e study was approved by the local ethics committee. Investigators were not required to ask patients for informed consent.
Findings
Ninety-three patients had received NSAIDs (that is, ibuprofen, diclofenac, or indomethacin) during their ICU stay. Th ere was no diff erence in APACHE (Acute Physiology and Chronic Health Evaluation) II score at ICU admission, but there were signifi cant diff erences in age, gender, and length of ICU stay. In-hospital mortality was about 10% lower in NSAID users in comparison with non-users (Table 1) . Medication during ICU stay with low-dose aspirin, clopidogrel, or statins, all three of which are believed to have a benefi t on the outcome in sepsis, is also indicated in Table 1 . A model of stepwise logistic regression with in-hospital mortality as a dependent variable and age, gender, APACHE II score, and the administration of NSAIDs, aspirin, clopidogrel, and statins as independent variables indicated that administration of aspirin during ICU stay was associated with a decreased mortality indicated by an odds ratio (OR) of 0.57 (95% confi dence interval 0.39 to 0.83) but that NSAIDs, clopidogrel, statins, and gender were without signifi cant eff ects. How ever, when patients on aspirin were excluded from the analysis, NSAIDs were
Abstract
Analyzing medical records of 979 patients with severe sepsis or septic shock provided some evidence that the use of low-dose aspirin or non-steroidal antiinfl ammatory drugs (NSAIDs) was associated with decreased hospital mortality. However, the benefi t was abolished when aspirin and NSAIDs were given together. also associated with a reduction of the in-hospital mortality (OR = 0.50, 0.26 to 0.94). On the other hand, the benefi t of aspirin (acetylsalicylic acid) was completely abolished in those patients who also received NSAIDs (OR = 1.12, 0.55 to 2.25). Th e data of the present study indicate that, given separately, both aspirin and NSAIDs may reduce mortality in patients with sepsis. Th e interaction between aspirin and NSAIDs needs to be considered in forthcoming trials looking for benefi ts of either compound in patients with sepsis. We speculate that the lack of benefi t of parallel use of aspirin and NSAIDs is due to a higher bleeding risk or anti-infl ammatory action or both.
